Opanac

Indications

• Opanac 0.1% Sterile Ophthalmic Suspension: Designed to alleviate post-operative ocular pain and inflammation, including after cataract surgery. It also helps inhibit surgery-induced miosis and prevent post-operative cystoid macular edema (CME).
• Opanac 0.3% Sterile Ophthalmic Suspension: Specifically targets post-operative pain and inflammation related to cataract surgery.

Pharmacology

• Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that, upon application, penetrates the cornea and is converted to Amfenac by ocular tissue hydrolase. Amfenac effectively inhibits the cyclooxygenase enzyme, crucial for prostaglandin synthesis and thus helps manage inflammation.

Dosage & Administration

• Opanac 0.1%: Instill 1 drop three times daily starting one day before cataract surgery, continuing through the first 2 weeks post-surgery for pain and inflammation. For surgery-induced miosis, apply 1 drop three times daily starting one day before surgery. For CME prevention, use 1 drop three times daily starting one day before surgery and continue for up to 6 weeks post-operatively.
• Opanac 0.3%: Instill 1 drop once daily starting one day before cataract surgery, continuing for 2 weeks post-surgery. Administer an additional drop 30 to 120 minutes before the surgery.

Contraindications

Not suitable for patients with known hypersensitivity to Nepafenac or other NSAIDs.

Side Effects

Potential side effects include a sensation of a foreign body, lid margin crusting, ocular discomfort, and hyperemia.

Pregnancy & Lactation

• Pregnancy: Limited studies are available; use only if the benefits outweigh potential risks to the fetus.
• Lactation: The excretion of Nepafenac in human milk is unknown; exercise caution when administering to nursing mothers.

Precautions & Warnings

Caution is advised for patients with bleeding tendencies or those on medications that prolong bleeding time.

Special Populations

• Children: Safety and effectiveness have not been established for patients under 18 years of age.
• Elderly: No significant differences in safety or effectiveness compared to younger patients.

Therapeutic Class

Ophthalmic Non-Steroidal Drugs